Pharmacist Discharge Medication Reconciliation Study

Not Applicable

Completed

• Conditions: Medication Reconciliation

• Registration Number: NCT01226589
• Lead Sponsor: Alberta Health services

Brief Summary

Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study Completion: 2008-10
• Study First Submitted: 2010-10-21
• Study First Submitted QC: 2010-10-21
• Study First Posted: 2010-10-22
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-18
• Last Update Posted: 2011-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Cancer inpatients under the care of Dr. Follett or Dr. Candler
• Cancer inpatients to be discharged from the CCI
• Patients >18 years of age
• Patients that are taking >1 medications or herbals total at home.

Exclusion Criteria

• Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
• Patients that do not remain in hospital >72 hours
• Patients without a home phone number or equivalent contact number.
• Language barrier (patients unable to speak or understand English).
• Patients that are readmitted and already included into the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
MRS Correlation with Treatment Response.	up to 1 year	The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute

Secondary Outcome Measures

Name	Time	Method
Correlation with Tumor Stage	up to 1 year	The amount of medication discrepancies after discharge that has the potential to cause moderate harm to severe harm.
The frequency of each type of unintentional medication discrepancies.

Trial Locations

Locations (1)

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada